ACE2 and COVID-19: In silico studies revealed DIZE’s strong affinity for RBD/ACE2, which is equivalent to other ARBs that have shown protective effects in COVID-19 patients in clinical practice [50,51,52,53,54,55,56,57,58,59,60,61,62,63,64].